Please use this identifier to cite or link to this item: http://hdl.handle.net/10553/52991
Title: Valsartan in patients with arterial hypertension and type 2 diabetes mellitus. The lapaval study
Authors: Perez, JCR 
Novoa, JN
Caballero, A
Anabitarte, A
Plaza, C
Palop, L
Esparragon, FR 
Keywords: Blood-Pressure
Antihypertensive Treatment
Progression
Outcomes
Risk
Issue Date: 2005
Publisher: 0211-6995
Journal: Nefrologia 
Abstract: Arterial hypertension and diabetes mellitus give rise to a situation of high cardiovascular risk. The potential renoprotection from inhibition of the renin-angiotensin system is a valid option in this type of patient.Objective: Evaluate the effect of valsartan on blood pressure (BP) and renal function in albuminuric patients with type 2 diabetes and arterial hypertension. Patients and methods: This was a prospective, observational study. Seventy-four diabetic patients with a blood pressure of >= 140/90 mmHg, with micro or macroalbuminuria and a) blood creatinine levels lower 1.5 mg/dl (group 1) or b) blood creatinine levels between 1.5 and 2 mg/dl (group 2), were studied and followed up for a 12-week period. Treatment was started with valsartan 80 mg/d, increasing to 760 mg/d, adding torasemide at a dose of 5 mg/d if the target blood pressure of 730185 mmHg has not been achieved. The degree of BP reduction was analyzed comparatively using a mercury sphygmomanometer and a semi-automatic monitor, the Omron HEM 705 CP.Results: All patients showed a significant reduction of the systolic (SBP) and diastolic (DBP) blood pressures (p < 0.001) over the study period, decreasing from 150.7 +/- 72.8 to 130.8 +/- 9.6 and from 94.7 +/- 7.7 to 76.8 +/- 6.3 mmHg, respectively. A significant reduction was observed only for diastolic blood pressure (101.4 +/- 8.8 to 79.4 +/- 5.6; p < 0.001) in the group 2 of patients. Lowest BP values were always obtained with the semiautomatic device. At the end of the study, 9.5% maintained valsartan 80 mg/d and 36.5% required the addition of a second or third drug to valsartan 160 mg in order to achieve the therapeutic target BP A significant reduction was observed in the microalbuminuria (75.5 +/- 9.5 to 54.7 +/- 7.3 mu g/min; p < 0.007) and macroalbuminuria (n = 20; 0.93 +/- 0.4 to 0.68 +/- 0.4 g/day; p < 0.001).Conclusion: Valsartan significantly reduced SBP and DBP Valsartan at 760 mg/d had a significantly greater effect in reducing micro and macroalbuminuria. No changes were observed in renal function, HbA1c or serum potassium. The rate of adverse events was very low.
URI: http://hdl.handle.net/10553/52991
ISSN: 0211-6995
Source: Nefrologia[ISSN 0211-6995],v. 25 (5), p. 500-508
Appears in Collections:Artículos
Show full item record

WEB OF SCIENCETM
Citations

1
checked on May 9, 2021

Page view(s)

10
checked on May 15, 2021

Google ScholarTM

Check


Share



Export metadata



Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.